ABSTRACT
Polycomb-repressive complex 1 (PRC1) has a central role in the regulation of heritable gene silencing during differentiation and development. PRC1 recruitment is generally attributed to interaction of the chromodomain of the core protein Polycomb with trimethyl histone H3K27 (H3K27me3), catalyzed by a second complex, PRC2. Unexpectedly we find that RING1B, the catalytic subunit of PRC1, and associated monoubiquitylation of histone H2A are targeted to closely overlapping sites in wild-type and PRC2-deficient mouse embryonic stem cells (mESCs), demonstrating an H3K27me3-independent pathway for recruitment of PRC1 activity. We show that this pathway is mediated by RYBP-PRC1, a complex comprising catalytic subunits of PRC1 and the protein RYBP. RYBP-PRC1 is recruited to target loci in mESCs and is also involved in Xist RNA-mediated silencing, the latter suggesting a wider role in Polycomb silencing. We discuss the implications of these findings for understanding recruitment and function of Polycomb repressors.
Subject(s)
Embryonic Stem Cells/metabolism , Histones/metabolism , Repressor Proteins/metabolism , Animals , Cell Line , Fibroblasts/metabolism , Mice , Polycomb Repressive Complex 1 , Polycomb Repressive Complex 2 , Polycomb-Group Proteins , Repressor Proteins/genetics , Ubiquitin-Protein Ligases/metabolism , UbiquitinationABSTRACT
The phenotypes associated with MED12 pathogenic variants are diverse. Male patients usually have missense variants, but the effects of base substitutions on mRNA splicing have not been investigated. Here, we report a Japanese brother with intellectual disability, characteristic facial appearance with blepharophimosis, cleft palate, Fallot tetralogy, vesicoureteral reflux, and deafness. A known missense pathogenic variant was detected in MED12, NM_005120.3:c.887G>A p.(Arg296Gln), and X-linked Ohdo syndrome was diagnosed in combination with their phenotype. mRNA splicing of MED12 was evaluated qualitatively and quantitatively using long-range PCR-based targeted RNA sequencing (reverse transcribed long amplicon sequencing), and it was shown that this missense variant simultaneously causes aberrant splicing of the 42-bp in-frame deletion in exon 7, r.847_888del, which accounts for approximately 30% of the mRNAs in both siblings. The X chromosome inactivation study showed that the X chromosome carrying the mutant allele was 100% inactivated in the carrier mothers. mRNA level analysis is essential for the accurate interpretation of the effects of variants. In this case, the MED12 protein function may be reduced by more than just an amino acid substitution, resulting in the patients with the most severe phenotype of MED12-related syndrome in males.
Subject(s)
Blepharophimosis , Mediator Complex , RNA Splicing , Child , Female , Humans , Male , Abnormalities, Multiple , Blepharophimosis/genetics , Blepharophimosis/pathology , Blepharoptosis , Cleft Palate/genetics , Cleft Palate/pathology , Deafness/genetics , Deafness/pathology , Genetic Diseases, X-Linked/genetics , Genetic Diseases, X-Linked/pathology , Heart Defects, Congenital , Intellectual Disability/genetics , Intellectual Disability/pathology , Mediator Complex/genetics , Mutation, Missense , Pedigree , Phenotype , RNA Splicing/genetics , Vesico-Ureteral Reflux/genetics , Vesico-Ureteral Reflux/pathology , X Chromosome Inactivation/geneticsABSTRACT
RNA sequencing (RNA-Seq) is a powerful technique and is increasingly being used in clinical research and drug development. Currently, several RNA-Seq methods have been developed. However, the relative advantage of each method for degraded RNA and low-input RNA, such as RNA samples collected in the field of clinical setting, has remained unknown. The Standard method of RNA-Seq captures mRNA by poly(A) capturing using Oligo dT beads, which is not suitable for degraded RNA. Here, we used three commercially available RNA-Seq library preparation kits (SMART-Seq, xGen Broad-range, and RamDA-Seq) using random primer instead of Oligo dT beads. To evaluate the performance of these methods, we compared the correlation, the number of detected expressing genes, and the expression levels with the Standard RNA-Seq method. Although the performance of RamDA-Seq was similar to that of Standard RNA-Seq, the performance for low-input RNA and degraded RNA has decreased. The performance of SMART-Seq was better than xGen and RamDA-Seq in low-input RNA and degraded RNA. Furthermore, the depletion of ribosomal RNA (rRNA) improved the performance of SMART-Seq and xGen due to increased expression levels. SMART-Seq with rRNA depletion has relative advantages for RNA-Seq using low-input and degraded RNA.
Subject(s)
RNA Stability , Sequence Analysis, RNA , Sequence Analysis, RNA/methods , Humans , Gene Expression Profiling/methods , High-Throughput Nucleotide Sequencing/methods , RNA/genetics , RNA, Ribosomal/genetics , RNA, Messenger/genetics , RNA-Seq/methodsABSTRACT
BACKGROUND: mRNA sequencing is a powerful technique, which is used to investigate the transcriptome status of a gene of interest, such as its transcription level and splicing variants. Presently, several RNA sequencing (RNA-Seq) methods have been developed; however, the relative advantage of each method has remained unknown. Here we used three commercially available RNA-Seq library preparation kits; the traditional method (TruSeq), in addition to full-length double-stranded cDNA methods (SMARTer and TeloPrime) to investigate the advantages and disadvantages of these three approaches in transcriptome analysis. RESULTS: We observed that the number of expressed genes detected from the TeloPrime sequencing method was fewer than that obtained using the TruSeq and SMARTer. We also observed that the expression patterns between TruSeq and SMARTer correlated strongly. Alternatively, SMARTer and TeloPrime methods underestimated the expression of relatively long transcripts. Moreover, genes having low expression levels were undetected stochastically regardless of any three methods used. Furthermore, although TeloPrime detected a significantly higher proportion at the transcription start site (TSS), its coverage of the gene body was not uniform. SMARTer is proposed to be yielded for nonspecific genomic DNA amplification. In contrast, the detected splicing event number was highest in the TruSeq. The percent spliced in index (PSI) of the three methods was highly correlated. CONCLUSIONS: TruSeq detected transcripts and splicing events better than the other methods and measured expression levels of genes, in addition to splicing events accurately. However, although detected transcripts and splicing events in TeloPrime were fewer, the coverage at TSS was highest. Additionally, SMARTer was better than TeloPrime with regards to the detected number of transcripts and splicing events among the understudied full-length double-stranded cDNA methods. In conclusion, for short-read sequencing, TruSeq has relative advantages for use in transcriptome analysis.
Subject(s)
Gene Expression Profiling , Transcriptome , Alternative Splicing , DNA, Complementary/genetics , Gene Expression Profiling/methods , High-Throughput Nucleotide Sequencing/methods , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA-Seq , Sequence Analysis, RNA/methodsABSTRACT
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by multiple dysplastic organ lesions and neuropsychiatric symptoms, caused by loss of function mutations in either TSC1 or TSC2. Genotype and phenotype analyses are conducted worldwide, but there have been few large-scale studies on Japanese patients, and there are still many unclear points. This study analyzed 283 Japanese patients with TSC (225 definite, 53 possible, and 5 genetic diagnoses). A total of 200 mutations (64 TSC1, 136 TSC2) were identified, of which 17 were mosaic mutations, 11 were large intragenic deletions, and four were splicing abnormalities due to deep intronic mutations. Several lesions and symptoms differed in prevalence and severity between TSC1 and TSC2 patients and were generally more severe in TSC2 patients. Moreover, TSC2 missense and in-frame mutations may attenuate skin and renal symptoms compared to other TSC2 mutations. Genetic testing revealed that approximately 20% of parents of a proband had mild TSC, which could have been missed. The patient demographics presented in this study revealed a high frequency of TSC1 patients and a low prevalence of epilepsy compared to global statistics. More patients with mild neuropsychiatric phenotypes were diagnosed in Japan, seemingly due to a higher utilization of brain imaging, and suggesting the possibility that a significant amount of mild TSC patients may not be correctly diagnosed worldwide.
Subject(s)
Tuberous Sclerosis , Humans , DNA Mutational Analysis/methods , Genotype , Japan/epidemiology , Mutation , Phenotype , Tuberous Sclerosis/epidemiology , Tuberous Sclerosis/genetics , Tuberous Sclerosis Complex 1 Protein/genetics , Tuberous Sclerosis Complex 2 Protein/genetics , Tumor Suppressor Proteins/geneticsABSTRACT
Malignant pleural effusion (MPE) provides a liquid tumor microenvironment model that includes cancer cells and immune cells. However, the characteristics of tumor antigen-specific CD8+ T cells have not been investigated in detail. Here, we analyzed MPE samples taken from a patient with pancreatic cancer who received a dendritic cell vaccine targeting Wilms' Tumor 1 (WT1) antigen over the disease course (two points at MPE1st and 2nd, two months after MPE1st). Epithelial cell adhesion molecule (EpCAM)+ cancer cells (PD-L1- or T cell immunoglobulin mucin-3, TIM-3-), both PD-1 or TIM-3 positive CD8+ T cells, and CD14+CD68+CD163+TIM-3+ macrophages increased from the MPE1st to MPE2nd. The ratio of WT1-specific cytotoxic lymphocytes (WT1-CTLs) to MPE CD8+ T cells and IFN-γ secretion of WT1-CTLs were reduced with disease progression. Coincidentally, the fraction of central memory T (TCM) of WT1-CTLs was decreased. On the other hand, CD8+ T cells in response to SMAD4P130L, which is homogeneously expressed in EpCAM+ cancer cells, were detected using in vitro expansion with the HLA-A*11:01 restrictive SVCVNLYH neoantigen. Furthermore, the CD8+ T cell response to SMAD4P130L was diminished following remarkably decreased numbers of CD8+ TCM in MPE samples. In conclusion, CD8+ T cells responding to WT1 or SMAD4P130L neoantigen expressed in EpCAM+ pancreatic cancer cells were detected in MPE. A tumor antigen-specific immune response would provide novel insight into the MPE microenvironment.
Subject(s)
Pancreatic Neoplasms , Pleural Effusion, Malignant , Vaccines , Humans , Epithelial Cell Adhesion Molecule/metabolism , CD8-Positive T-Lymphocytes , B7-H1 Antigen/metabolism , Hepatitis A Virus Cellular Receptor 2/metabolism , WT1 Proteins , Programmed Cell Death 1 Receptor/metabolism , Mucin-3/metabolism , Pancreatic Neoplasms/pathology , Immunoglobulins/metabolism , Vaccines/metabolism , HLA-A Antigens , Tumor Microenvironment , Smad4 Protein/metabolismABSTRACT
BACKGROUND AND PURPOSE: The purpose of this study was to assess nationwide incidence and outcomes of aneurysmal subarachnoid hemorrhage (aSAH). The Swiss SOS (Swiss Study on Subarachnoid Hemorrhage) was established in 2008 and offers the unique opportunity to provide this data from the point of care on a nationwide level. METHODS: All patients with confirmed aneurysmal subarachnoid hemorrhage admitted between January 1, 2009 and December 31, 2014, within Switzerland were recorded in a prospective registry. Incidence rates were calculated based on time-matched population data. Admission parameters and outcomes at discharge and at 1 year were recorded. RESULTS: We recorded data of 1787 consecutive patients. The incidence of aneurysmal subarachnoid hemorrhage in Switzerland was 3.7 per 100 000 persons/y. The number of female patients was 1170 (65.5%). With a follow-up rate of 91.3% at 1 year, 1042 patients (58.8%) led an independent life according to the modified Rankin Scale (0-2). About 1 in 10 patients survived in a dependent state (modified Rankin Scale, 3-5; n=185; 10.4%). Case fatality was 20.1% (n=356) at discharge and 22.1% (n=391) after 1 year. CONCLUSIONS: The current incidence of aneurysmal subarachnoid hemorrhage in Switzerland is lower than expected and an indication of a global trend toward decreasing admissions for ruptured intracranial aneurysms. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03245866.
Subject(s)
Subarachnoid Hemorrhage/epidemiology , Subarachnoid Hemorrhage/therapy , Adult , Aged , Aged, 80 and over , Aneurysm, Ruptured/epidemiology , Aneurysm, Ruptured/mortality , Aneurysm, Ruptured/therapy , Female , Follow-Up Studies , Humans , Incidence , Independent Living , Male , Middle Aged , Prospective Studies , Registries , Sex Factors , Subarachnoid Hemorrhage/mortality , Survival Analysis , Switzerland/epidemiology , Treatment OutcomeABSTRACT
Elaborate analyses of the status of gene mutations in neurofibromatosis type 1 (NF1) are still difficult nowadays due to the large gene sizes, broad mutation spectrum, and the various effects of mutations on mRNA splicing. These problems cannot be solved simply by sequencing the entire coding region using next-generation sequencing (NGS). We recently developed a new strategy, named combined long amplicon sequencing (CoLAS), which is a method for simultaneously analysing the whole genomic DNA region and, also, the full-length cDNA of the disease-causative gene with long-range PCR-based NGS. In this study, CoLAS was specifically arranged for NF1 genetic analysis, then applied to 20 patients (five previously reported and 15 newly recruited patients, including suspicious cases) for optimising the method and to verify its efficacy and benefits. Among new cases, CoLAS detected not only 10 mutations, including three unreported mutations and one mosaic mutation, but also various splicing abnormalities and allelic expression ratios quantitatively. In addition, heterozygous mapping by polymorphisms, including introns, showed copy number monitoring of the entire NF1 gene region was possible in the majority of patients tested. Moreover, it was shown that, when a chromosomal level microdeletion was suspected from heterozygous mapping, it could be detected directly by breakpoint-specific long PCR. In conclusion, CoLAS not simply detect the causative mutation but accurately elucidated the entire structure of the NF1 gene, its mRNA expression, and also the splicing status, which reinforces its high usefulness in the gene analysis of NF1.
Subject(s)
Biomarkers, Tumor/genetics , High-Throughput Nucleotide Sequencing/methods , Mutation , Neurofibromatosis 1/genetics , Alleles , Biomarkers, Tumor/metabolism , High-Throughput Nucleotide Sequencing/standards , Humans , Neurofibromatosis 1/metabolism , Neurofibromatosis 1/pathology , Pilot Projects , Polymerase Chain Reaction/methods , RNA SplicingABSTRACT
Alternative splicing is a regulated process by which eukaryotic genes may produce diverse biological products. Defects in the process typically affect cellular function and can lead to disease. Next-generation sequencing (NGS) technologies have been developed to detect alternative splicing events; however, the alternative splicing events detected by standard RNA-Seq may or may not be derived from full-length RNA. The SMARTer method provides full-length double-strand cDNA synthesis, and the resulting gene expression patterns correlate strongly with standard RNA-Seq. However, it also yields non-specific genomic DNA amplification. We improved the SMARTer method by employing a target-capture full-length double-strand cDNA sequencing method. High-fidelity, full-length cDNA is generated by the SMARTer method, followed by target-specific capture with exon probes. The expression pattern observed with this SMARTer Capture method was highly correlated with the results of the original SMARTer method. The number and accuracy of the detected splicing events were increased by eliminating non-specific genomic DNA amplification by the SMARTer Capture. Compared to the original SMARTer method, the SMARTer Capture provided 4-fold greater detection of alternative splicing events at the same read number, and it took less than 1/100 of read number to detect the same number of splicing events. The percent splicing in index (PSI) of the SMARTer Capture is highly correlated with the PSI of the SMARTer. These results indicate that the SMARTer Capture represents an improvement of the SMARTer method to accurately characterize alternative splicing repertories in targeted genes without biases.
Subject(s)
Alternative Splicing , DNA, Complementary/genetics , DNA/genetics , High-Throughput Nucleotide Sequencing/methods , RNA, Messenger/genetics , Sequence Analysis, RNA/methods , Tuberous Sclerosis/genetics , Humans , Software , Tuberous Sclerosis/bloodABSTRACT
Sox2 is a transcription factor required for the maintenance of pluripotency. It also plays an essential role in different types of multipotent stem cells, raising the possibility that Sox2 governs the common stemness phenotype. Here we show that Sox2 is a critical downstream target of fibroblast growth factor (FGF) signaling, which mediates self-renewal of trophoblast stem cells (TSCs). Sustained expression of Sox2 together with Esrrb or Tfap2c can replace FGF dependency. By comparing genome-wide binding sites of Sox2 in embryonic stem cells (ESCs) and TSCs combined with inducible knockout systems, we found that, despite the common role in safeguarding the stem cell state, Sox2 regulates distinct sets of genes with unique functions in these two different yet developmentally related types of stem cells. Our findings provide insights into the functional versatility of transcription factors during embryogenesis, during which they can be recursively utilized in a variable manner within discrete network structures.
Subject(s)
Cell Differentiation/genetics , Embryonic Stem Cells/metabolism , SOXB1 Transcription Factors/metabolism , Trophoblasts/metabolism , Animals , Cell Line , Embryonic Development/genetics , Embryonic Stem Cells/cytology , Fibroblast Growth Factors/metabolism , Gene Expression Regulation, Developmental , Mice , Pluripotent Stem Cells/cytology , Pluripotent Stem Cells/metabolism , SOXB1 Transcription Factors/immunology , Signal Transduction/genetics , Stem Cells/cytology , Stem Cells/metabolism , Transcription Factor AP-2/metabolism , Trophoblasts/cytologyABSTRACT
Human hereditary malformation syndromes are caused by mutations in the genes of the signal transduction molecules involved in fetal development. Among them, the Sonic hedgehog (SHH) signaling pathway is the most important, and many syndromes result from its disruption. In this review, we summarize the molecular mechanisms and role in embryonic morphogenesis of the SHH pathway, then classify the phenotype of each malformation syndrome associated with mutations of major molecules in the pathway. The output of the SHH pathway is shown as GLI activity, which is generated by SHH in a concentration-dependent manner, i.e., the sum of activating form of GLI (GLIA) and repressive form of GLI (GLIR). Which gene is mutated and whether the mutation is loss-of-function or gain-of-function determine in which concentration range of SHH the imbalance occurs. In human malformation syndromes, too much or too little GLI activity produces symmetric phenotypes affecting brain size, craniofacial (midface) dysmorphism, and orientation of polydactyly with respect to the axis of the limb. The symptoms of each syndrome can be explained by the GLIA/R balance model.
Subject(s)
Craniofacial Abnormalities/etiology , Hedgehog Proteins/metabolism , Limb Deformities, Congenital/etiology , Cilia/physiology , Craniofacial Abnormalities/genetics , Gene Expression Regulation, Developmental , Hedgehog Proteins/genetics , Humans , Kinesins/genetics , Kinesins/metabolism , Limb Deformities, Congenital/genetics , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Patched-1 Receptor/genetics , Patched-1 Receptor/metabolism , Repressor Proteins/genetics , Repressor Proteins/metabolism , Syndrome , Zinc Finger Protein Gli2/genetics , Zinc Finger Protein Gli2/metabolismABSTRACT
Published single-cell datasets are rich resources for investigators who want to address questions not originally asked by the creators of the datasets. The single-cell datasets might be obtained by different protocols and diverse analysis strategies. The main challenge in utilizing such single-cell data is how we can make the various large-scale datasets to be comparable and reusable in a different context. To challenge this issue, we developed the single-cell centric database 'SCPortalen' (http://single-cell.clst.riken.jp/). The current version of the database covers human and mouse single-cell transcriptomics datasets that are publicly available from the INSDC sites. The original metadata was manually curated and single-cell samples were annotated with standard ontology terms. Following that, common quality assessment procedures were conducted to check the quality of the raw sequence. Furthermore, primary data processing of the raw data followed by advanced analyses and interpretation have been performed from scratch using our pipeline. In addition to the transcriptomics data, SCPortalen provides access to single-cell image files whenever available. The target users of SCPortalen are all researchers interested in specific cell types or population heterogeneity. Through the web interface of SCPortalen users are easily able to search, explore and download the single-cell datasets of their interests.
Subject(s)
Databases, Genetic , Datasets as Topic , Mice/genetics , Single-Cell Analysis , Transcriptome , Animals , Data Accuracy , Data Curation , Gene Expression , Gene Ontology , Humans , Molecular Sequence Annotation , User-Computer Interface , WorkflowABSTRACT
Cancer gene panel testing requires accurate detection of somatic mosaic mutations, as the test sample consists of a mixture of cancer cells and normal cells; each minor clone in the tumor also has different somatic mutations. Several studies have shown that the different types of software used for variant calling for next generation sequencing (NGS) can detect low-frequency somatic mutations. However, the accuracy of these somatic variant callers is unknown. We performed cancer gene panel testing in duplicate experiments using three different high-fidelity DNA polymerases in pre-capture amplification steps and analyzed by three different variant callers, Strelka2, Mutect2, and LoFreq. We selected six somatic variants that were detected in both experiments with more than two polymerases and by at least one variant caller. Among them, five single nucleotide variants were verified by CEL nuclease-mediated heteroduplex incision with polyacrylamide gel electrophoresis and silver staining (CHIPS) and Sanger sequencing. In silico analysis indicated that the FBXW7 and MAP3K1 missense mutations cause damage at the protein level. Comparing three somatic variant callers, we found that Strelka2 detected more variants than Mutect2 and LoFreq. We conclude that dual sequencing with Strelka2 analysis is useful for detection of accurate somatic mutations in cancer gene panel testing.
Subject(s)
Genes, Neoplasm , High-Throughput Nucleotide Sequencing/methods , Mutation/genetics , Neoplasms/genetics , Base Sequence , DNA-Directed DNA Polymerase/metabolism , Female , Gene Frequency/genetics , Humans , Middle Aged , Reproducibility of ResultsABSTRACT
Transcription factors and epigenetic modulators are involved in the maintenance of self-renewal in embryonic stem (ES) cells. Here, we demonstrate the existence of a regulatory loop in ES cells between Sox2, an indispensable transcription factor for self-renewal, and embryonic ectoderm development (Eed), an epigenetic modulator regulating histone methylation. We found that Sox2 and Eed positively regulate each other's expression. Interestingly, Sox2 overexpression suppressed the induction of differentiation-associated genes in Eed-deficient ES cells without restoring histone methylation. This Sox2-mediated suppression was prevented by knockdown of the histone acetyltransferase (HAT), Tip60 or Elp3, and Sox2 stimulated expression of these HATs. Furthermore, forced expression of either HAT resulted in repression of differentiation-associated genes in Eed-deficient cells. These results suggest that Sox2 overcame the phenotype of Eed-deficient ES cells by promoting histone acetylation. We also found that knockout of Eed and knockdown of these HATs synergistically enhanced the upregulation of differentiation-associated genes in ES cells. Taken together, our results suggest that the Eed/Sox2 regulatory loop contributes to the maintenance of self-renewal in ES cells by controlling histone methylation and acetylation.
Subject(s)
Embryonic Stem Cells/physiology , Gene Expression Regulation , Histones/metabolism , Repressor Proteins/biosynthesis , SOXB1 Transcription Factors/biosynthesis , Acetylation , Gene Knockdown Techniques , Gene Knockout Techniques , Humans , Methylation , Polycomb Repressive Complex 2 , Repressor Proteins/genetics , SOXB1 Transcription Factors/geneticsABSTRACT
BACKGROUND: Comparison of artery diameters between CT angiography (CTA) and subtraction arteriography (DSA) has the limitation that measurements on DSA are provided as relative units, making a quantitative comparison difficult. On CTA, artery diameters may depend on windowing settings and may lead to false measurements. This study assesses the correlation between CTA and DSA based on measurements in a basic imaging viewer using normalized DSA values, and assesses whether the validity is time dependent. METHODS: Patients with aneurysmal subarachnoid hemorrhage (aSAH) were included if they underwent both CTA and DSA within 24 h. The analysis was performed using the basic imaging application Centricity Enterprise PACS viewer (GE Healthcare). A total of 15 arterial locations were assessed on CTA and DSA and a specific measurement protocol with normalization of all artery diameters to the cavernous segment of the internal carotid artery was used. Pearson correlation analysis was calculated to access the correlation of normalized arterial diameters measured with both methods at admission and at clinical onset of CVS. RESULTS: A total of 627 arteries in 38 patients were analyzed in both CTA and DSA. There was a significant correlation coefficient (R = 0.706) of artery diameters between CTA and DSA measures (p < 0.0001). This correlation remained high when comparing CTA and DSA at admission (correlation coefficient: 0.641; p < 0.0001) vs. in the vasospasm period (0.835; p < 0.0001). The correlation was good in all proximal artery segments and lost significance only when distal vessel segments were considered. CONCLUSION: Using basic imaging viewers, mostly accessible for clinicians, CTA is a noninvasive and reliable method to assess proximal arterial diameters of the brain in the management of cerebral vasospasm in the acute phase after aSAH. Significance is reached, independent of whether CTA is obtained in the acute phase or during the period of vasospasm, by normalization of basal cerebral artery diameters to a non-variable anatomic landmark, i.e., the petrous or cavernous internal carotid artery diameter.
Subject(s)
Cerebral Angiography/methods , Cerebral Arteries/diagnostic imaging , Subarachnoid Hemorrhage/diagnostic imaging , Tomography, X-Ray Computed/methods , Vasospasm, Intracranial/diagnostic imaging , Adult , Angiography, Digital Subtraction/methods , Anterior Cerebral Artery/diagnostic imaging , Carotid Artery, Internal/diagnostic imaging , Databases, Factual , Female , Humans , Male , Middle Aged , Middle Cerebral Artery/diagnostic imaging , Posterior Cerebral Artery/diagnostic imaging , Retrospective Studies , Subarachnoid Hemorrhage/complications , Vasospasm, Intracranial/etiologyABSTRACT
BACKGROUND: Cortical and subcortical brain ischemia following aneurysmal subarachnoid hemorrhage (aSAH) remains a central challenge in improving patient outcome. Generally the bone flap is replaced after surgical clipping and no decompression is practiced in endovascularly treated patients. The aim of this preliminary safety and feasibility study is to clarify whether a first-line decompression would improve brain perfusion and salvage more tissue at risk in patients who developed delayed vasospasm. In addition, we assessed whether the risks involved with a second surgery to replace the bone flap would affect patient outcome. METHODS: We retrospectively analyzed patients with aSAH who underwent surgical clipping and developed cerebral vasospasm from 2009 to 2012 at our institution. We selected cases where the bone flap was not replaced at initial surgery and needed a second procedure for bone flap replacement. Primary end points were new delayed ischemic neurological deficits (DINDs), the extent of brain infarctions, and patient functional outcome. Secondary end points were hazards of the second procedure for bone replacement. RESULTS: We identified six patients in whom the surgeon chose not to replace the bone flap. In four patients, this was a pterional bone flap (standard), and in two patients it was a larger frontotemporoparietal flap. Despite the limited extent of the craniotomy, only one patient (16 %) required additional decompression. Two patients (33%) developed DINDs and five patients (83 %) showed delayed cerebral infarctions on computed tomography. Of those, three patients showed good outcome (Glasgow Outcome Scale score >4 and modified Rankin Scale score <3). No complications or new neurological deficits occurred during the second surgery for bone replacement. CONCLUSIONS: To date, no standardized criteria exist to decide whether the bone flap should be removed or replaced at initial surgery. Our single-center experience in a limited number of patients reveals a pattern with respect to initial clinical parameters and imaging findings that might be a first step in developing standardized decision parameters. This may prevent secondary surgery for decompression in deleterious conditions during the vasospasm phase. Based on these findings, we have developed a protocol for a prospective study that will further investigate the benefits of this management.
Subject(s)
Brain Ischemia/prevention & control , Craniotomy/methods , Decompression, Surgical/methods , Intracranial Aneurysm/surgery , Skull/surgery , Subarachnoid Hemorrhage/surgery , Adult , Aneurysm, Ruptured/complications , Aneurysm, Ruptured/diagnostic imaging , Aneurysm, Ruptured/surgery , Brain Ischemia/diagnostic imaging , Brain Ischemia/etiology , Cerebrovascular Circulation , Craniotomy/adverse effects , Decompression, Surgical/adverse effects , Feasibility Studies , Female , Humans , Intracranial Aneurysm/complications , Intracranial Aneurysm/diagnostic imaging , Male , Middle Aged , Retrospective Studies , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/diagnostic imaging , Surgical Flaps , Tomography, X-Ray ComputedABSTRACT
Here, we report a novel PROS1 splicing mutation in a patient with type I protein S deficiency. Qualitative and quantitative analysis of pathogenic splicing variants at the mRNA level was performed by long-range PCR-based targeted DNA and RNA sequencing. A base substitution in the exon 4 splicing donor site activates a potential splicing donor site in intron 4, resulting in an in-frame insertion of 48 bases (16 amino acids).
ABSTRACT
X-linkded Ohdo syndrome is characterized mainly by intellectual disability, delays in reaching development, feeding difficulties, thyroid dysfunction, and dysmorphic appearance with blepharophimosis, immobile mask-like face and bulbous nose. The X-linked Ohdo syndrome is caused by loss of function mutation in MED12 gene on X chromosome. The peripheral blood mononuclear cells from a patient carrying missense mutation of the MED12 gene were reprogrammed using the CytoTune-iPS2.0 Sendai Reprogramming Kit. The missense mutation in MED12 gene causes the abnormal protein variant. The established human induced pluripotent cell line will enable proper in vitro disease modelling of X-linked Ohdo syndrome.
Subject(s)
Induced Pluripotent Stem Cells , Mediator Complex , Mutation, Missense , Humans , Induced Pluripotent Stem Cells/metabolism , Mediator Complex/genetics , Mediator Complex/metabolism , Cell Line , Male , Cellular Reprogramming , Genetic Diseases, X-Linked/genetics , Genetic Diseases, X-Linked/pathologyABSTRACT
There are limited methods to stably analyze the interactions between cancer cells and glial cells in vitro, which hinders our molecular understanding. Here, we develop a simple and stable culture method of mouse glial cells, termed mixed-glial culture on/in soft substrate (MGS), which serves well as a platform to study cancer-glia interactions. Using this method, we find that human lung cancer cells become overly dependent on metabotropic glutamate receptor 1 (mGluR1) signaling in the brain microenvironment. Mechanistically, interactions with astrocytes induce mGluR1 in cancer cells through the Wnt-5a/prickle planar cell polarity protein 1 (PRICKLE1)/RE1 silencing transcription factor (REST) axis. Induced mGluR1 directly interacts with and stabilizes the epidermal growth factor receptor (EGFR) in a glutamate-dependent manner, and these cells then become responsive to mGluR1 inhibition. Our results highlight increased dependence on mGluR1 signaling as an adaptive strategy and vulnerability of human lung cancer brain metastasis.
Subject(s)
Brain Neoplasms , Lung Neoplasms , Receptors, Metabotropic Glutamate , Mice , Animals , Humans , Glutamic Acid , Astrocytes/metabolism , Receptors, Metabotropic Glutamate/metabolism , ErbB Receptors , Tumor MicroenvironmentABSTRACT
Tuberous sclerosis complex (TSC) is a relatively common autosomal dominant disorder characterized by multiple dysplastic organ lesions and neuropsychiatric symptoms caused by loss-of-function mutation of either TSC1 or TSC2. The genetic diagnosis of inherited diseases, including TSC, in the clinical field is widespread using next-generation sequencing. The mutations in protein-coding exon tend to be verified because mutations directly cause abnormal protein. However, it is relatively difficult to verify mutations in the intron region because it is required to investigate whether the intron mutations affect the abnormal splicing of transcripts. In this study, we developed a target-capture full-length double-stranded cDNA sequencing method using Nanopore long-read sequencer (Nanopore long-read target sequencing). This method revealed the occurrence of intron mutation in the TSC2 gene and found that the intron mutation produces novel intron retention splicing transcripts that generate truncated proteins. The protein-coding transcripts were decreased due to the expression of the novel intron retention transcripts, which caused TSC in patients with the intron mutation. Our results indicate that Nanopore long-read target sequencing is useful for the detection of mutations and confers information on the full-length alternative splicing of transcripts for genetic diagnosis.